Aimplas’ Pharmapacksafe Project Extends Eye Drop Shelf-life and Reduces Patient Visits

Validation of two packages for eye drops leads to extended shelf life and reduction of patient visits for hospital pharmacy and ophthalmological patients.

Aimplas, the Plastics Technology Centre, in conjunction with ISS La Fe, MicroBios and PFP Termopolímeros has completed the Pharmapacksafe project. The company says that this project, developed within the framework of the R&D national call Retos Colaboración and funded by the Spanish Ministry of Science, Innovation, and Universities, has successfully validated the inertia and stability of two plastic packages for eye drops that were discarded until now after a week.

The lack of information about the exact expiry date of the product in conditions of inertia and stability led hospital pharmacies to tell patients to have an appointment within seven days to get a new formulated drug, according to the company. The research conducted in the project has verified that the packaging of three different eye drops (based on tacrolimus, chlorhexidineand voriconazole) is designed to be safe for six, four, and six months stored at fridge, respectively.

This should reduce the number of tailored medications used as eye drops in hospital pharmacies with subsequent cost saving, as well as fewer appointments of patients to the hospital pharmacy.

Aimplas seeks to work on projects like these in order to improve people’s health within the framework of its commitment to the UN Sustainable Development Goals, in particular Goal 3 on health and well-being.

The Pharmapacksafe project is funded by ERDF/Ministry of Science, Innovation, and Universities-State Research Agency, which aims to promote technological development, innovation, and high-quality research.

Companies in this article
More in Pharmaceutical